184 related articles for article (PubMed ID: 33744350)
1. Red light photodynamic therapy with BF-200 ALA showed superior efficacy in the treatment of actinic keratosis on the extremities, trunk, and neck in a vehicle-controlled phase III study.
Ulrich M; Reinhold U; Dominicus R; Aschoff R; Szeimies RM; Dirschka T
J Am Acad Dermatol; 2021 Dec; 85(6):1510-1519. PubMed ID: 33744350
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz(®) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED(®) lamp.
Reinhold U; Dirschka T; Ostendorf R; Aschoff R; Berking C; Philipp-Dormston WG; Hahn S; Lau K; Jäger A; Schmitz B; Lübbert H; Szeimies RM
Br J Dermatol; 2016 Oct; 175(4):696-705. PubMed ID: 26921093
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo.
Dirschka T; Radny P; Dominicus R; Mensing H; Brüning H; Jenne L; Karl L; Sebastian M; Oster-Schmidt C; Klövekorn W; Reinhold U; Tanner M; Gröne D; Deichmann M; Simon M; Hübinger F; Hofbauer G; Krähn-Senftleben G; Borrosch F; Reich K; Berking C; Wolf P; Lehmann P; Moers-Carpi M; Hönigsmann H; Wernicke-Panten K; Helwig C; Foguet M; Schmitz B; Lübbert H; Szeimies RM;
Br J Dermatol; 2012 Jan; 166(1):137-46. PubMed ID: 21910711
[TBL] [Abstract][Full Text] [Related]
4. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis.
Dirschka T; Radny P; Dominicus R; Mensing H; Brüning H; Jenne L; Karl L; Sebastian M; Oster-Schmidt C; Klövekorn W; Reinhold U; Tanner M; Gröne D; Deichmann M; Simon M; Hübinger F; Hofbauer G; Krähn-Senftleben G; Borrosch F; Reich K; Berking C; Wolf P; Lehmann P; Moers-Carpi M; Hönigsmann H; Wernicke-Panten K; Hahn S; Pabst G; Voss D; Foguet M; Schmitz B; Lübbert H; Szeimies RM; ;
Br J Dermatol; 2013 Apr; 168(4):825-36. PubMed ID: 23252768
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, vehicle-controlled phase 2 study of blue light photodynamic therapy with aminolevulinic acid HCl 20% topical solution for the treatment of actinic keratoses on the upper extremities: the effect of occlusion during the drug incubation period.
Schmieder GJ; Huang EY; Jarratt M
J Drugs Dermatol; 2012 Dec; 11(12):1483-9. PubMed ID: 23377520
[TBL] [Abstract][Full Text] [Related]
6. A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis.
Dirschka T; Ekanayake-Bohlig S; Dominicus R; Aschoff R; Herrera-Ceballos E; Botella-Estrada R; Hunfeld A; Kremser M; Schmitz B; Lübbert H; Puig S
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):288-297. PubMed ID: 30022544
[TBL] [Abstract][Full Text] [Related]
7. Home- vs clinic-based daylight photodynamic therapy with 5-aminolevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis: A randomized, single-blind, prospective study.
Saenz-Guirado S; Ayen-Rodriguez A; Galvez-Moreno M; Velasco-Amador JP; Llamas-Molina JM; Ruiz-Villaverde R; Molina-Leyva A
Photodiagnosis Photodyn Ther; 2024 Apr; 46():104031. PubMed ID: 38438001
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of photodynamic therapy with amino-5-laevulinate nanoemulsion versus methyl-5-aminolaevulinate for actinic keratosis: A meta-analysis.
Fu C; Kuang BH; Qin L; Zeng XY; Wang BC
Photodiagnosis Photodyn Ther; 2019 Sep; 27():408-414. PubMed ID: 31310826
[TBL] [Abstract][Full Text] [Related]
9. The impact of occlusive vs non-occlusive application of 5-aminolevulinic acid (BF-200 ALA) on the efficacy and tolerability of photodynamic therapy for actinic keratosis on the scalp and face: A prospective within-patient comparison trial.
Meierhofer C; Silic K; Urban MV; Tanew A; Radakovic S
Photodermatol Photoimmunol Photomed; 2021 Jan; 37(1):56-62. PubMed ID: 32974974
[TBL] [Abstract][Full Text] [Related]
10. 5-aminolaevulinic acid nanoemulsion is more effective than methyl-5-aminolaevulinate in daylight photodynamic therapy for actinic keratosis: a nonsponsored randomized double-blind multicentre trial.
Räsänen JE; Neittaanmäki N; Ylitalo L; Hagman J; Rissanen P; Ylianttila L; Salmivuori M; Snellman E; Grönroos M
Br J Dermatol; 2019 Aug; 181(2):265-274. PubMed ID: 30329163
[TBL] [Abstract][Full Text] [Related]
11. Combined daylight and conventional photodynamic therapy with 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis of the face and scalp: a new and efficient approach.
Salido-Vallejo R; Jiménez-Nájar F; Garnacho-Sucedo G; Vélez A
Arch Dermatol Res; 2020 Nov; 312(9):675-680. PubMed ID: 31838569
[TBL] [Abstract][Full Text] [Related]
12. Daylight photodynamic therapy for actinic keratoses: a randomized double-blinded nonsponsored prospective study comparing 5-aminolaevulinic acid nanoemulsion (BF-200) with methyl-5-aminolaevulinate.
Neittaanmäki-Perttu N; Karppinen TT; Grönroos M; Tani TT; Snellman E
Br J Dermatol; 2014 Nov; 171(5):1172-80. PubMed ID: 25109244
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacokinetics and Safety of a 10% Aminolevulinic Acid Hydrochloride Nanoemulsion Gel (BF-200 ALA) in Photodynamic Therapy of Patients Extensively Affected With Actinic Keratosis: Results of 2 Maximal Usage Pharmacokinetic Trials.
Novak B; DuBois J; Chahrour O; Papusha T; Hirt S; Philippi T; Zogel C; Osenberg K; Schmitz B; Lübbert H
Clin Pharmacol Drug Dev; 2022 Apr; 11(4):535-550. PubMed ID: 34633154
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Vehicle-Controlled Phase 3 Study of Aminolevulinic Acid Photodynamic Therapy for the Treatment of Actinic Keratoses on the Upper Extremities.
Brian Jiang SI; Kempers S; Rich P; Marcus S; Houlihan A; Piacquadio D; Pariser D
Dermatol Surg; 2019 Jul; 45(7):890-897. PubMed ID: 30640777
[TBL] [Abstract][Full Text] [Related]
15. Plum-blossom needle tapping enhances the efficacy of ALA photodynamic therapy for facial actinic keratosis in Chinese population: a randomized, multicenter, prospective, and observer-blind study.
Wang P; Xie F; Zhang L; Zhao S; Zhu L; Shen S; Li D; Chen Z; Xiao R; Lu Y; Lei X; Li Y; Zhang G; Zeng W; Wang X
Photodiagnosis Photodyn Ther; 2023 Jun; 42():103611. PubMed ID: 37211296
[TBL] [Abstract][Full Text] [Related]
16. No room for pain: A prospective study showing effective and nearly pain-free treatment of actinic keratosis with simulated daylight photodynamic therapy (SDL-PDT) using the IndoorLux® System in combination with BF-200 ALA (Ameluz®).
Bai-Habelski JC; Medrano K; Palacio A; Reinhold U
Photodiagnosis Photodyn Ther; 2022 Mar; 37():102692. PubMed ID: 34923153
[TBL] [Abstract][Full Text] [Related]
17. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities.
Sotiriou E; Apalla Z; Maliamani F; Zaparas N; Panagiotidou D; Ioannides D
J Eur Acad Dermatol Venereol; 2009 Sep; 23(9):1061-5. PubMed ID: 19470041
[TBL] [Abstract][Full Text] [Related]
18. A randomized, blinded, bilateral intraindividual, vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities.
Taub AF; Garretson CB
J Drugs Dermatol; 2011 Sep; 10(9):1049-56. PubMed ID: 22052276
[TBL] [Abstract][Full Text] [Related]
19. A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis.
Reinhold U
Future Oncol; 2017 Nov; 13(27):2413-2428. PubMed ID: 28805092
[TBL] [Abstract][Full Text] [Related]
20. Daylight methyl-aminolevulinate photodynamic therapy versus ingenol mebutate for the treatment of actinic keratoses: an intraindividual comparative analysis.
Genovese G; Fai D; Fai C; Mavilia L; Mercuri SR
Dermatol Ther; 2016 May; 29(3):191-6. PubMed ID: 26799440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
